Connect with us

Pharmaceuticals

Pharmaceutical CDMO Services Market Highlights On Future Development 2028 – Cole Reports

Published

on

Global Pharmaceutical CDMO Services Market: Overview

The demand within the global market for pharmaceutical CDMO services has been rising on account of the need develop safe and effective drugs for the treatment of multiple diseases and disorders. Contract Development and Manufacturing Organisations (CDMO) are offshoots of the pharmaceutical industry that help pharmaceutical companies in manufacturing, research, and development of drugs and other pharmaceutical products. CDMO provides key services such as research about key drugs, development of specialised drugs, and final manufacturing of these drugs. The pharmaceutical industry has to cater to a wide range of operations which often results in aggravated quality of drugs or medications. Hence, in order to ensure that the manufacture of drugs is supported by a robust system that focuses on quality, performance, and safety of drugs, pharma companies have resortd to contract manufacturing. The use of contract development and manufacturing services not only helps pharmaceutical companies in maintaining drug-quality but also reduces their operational costs. Owing to the aforementioned factors, the demand within the global market for pharmaceutical CDMO services is anticipated to touch new heights in the years to come.

Get Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=4182

The global market for pharmaceutical CDMO services may be segmented on the basis of the following parameters: service-type, product type, and geography. It is essential to understand each of these segments in order to get deep insights about the global pharmaceutical CDMO services market.

A report on the global market for pharmaceutical CDMO services sheds value on multiple dynamics and trends that have aided the growth of the global market. Moreover, the resonant factors relating to the pharmaceutical industry that have aided market growth are also elucidated in the report.

Global Pharmaceutical CDMO Services Market: Trends and Opportunities

The demand within the global market for pharmaceutical CDMO services has been rising on account of the need to minimize production costs within the pharmaceutical industry. There have been several cases of demand-supply deficit in the pharmaceutical industry of various regions, and there is a dire need to match the supply of drugs to the demand within the market. This factor has led to the outsourcing of pharmaceutical production to contract manufacturing organisations which has in turn given an impetus to the growth of the global market for pharmaceutical CDMO services.

The manufacture of innovative drugs involves the deployment of substantial financial resources, and hence, it is important to achieve viability of operations within the pharmaceutical industry. Hence, to reap benefits from drug development, pharmaceutical companies outsource their manufacturing operations to CDMOs. Furthermore, the development of generic drugs has also gathered swing in recent times which has also given an impetus to the growth of the global market for pharmaceutical CDMO services.

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=4182

Global Pharmaceutical CDMO Services Market: Regional Outlook

On the basis of geography, the demand within the market for pharmaceutical CDMO services in Europe has been rising at a boisterous rate in recent times. This regional growth can be attributed due to the pragmatic approach towards contract manufacturing followed by pharmaceutical companies in England, France, Ireland, and Germany. Furthermore, the demand within the market for pharmaceutical CDMO services in Asia Pacific is also rising on account of the massive population in India and China.

Global Pharmaceutical CDMO Services Market: Competitive Landscape

Some of the key players in the global market for pharmaceutical CDMO services are AMRI Global, Recipharm AB, Patheon N.V., Catalent, Inc., Aenova Group, Amatsigroup, Strides Pharma Science Limited, WuXi AppTec Group, Piramal Pharma Solutions, and Siegfried Ltd.

Read Comprehensive Overview of Report @ https://www.tmrresearch.com/pharmaceutical-cdmo-services-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Pharmaceuticals

Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Down 3.8% After Earnings Miss

Published

on

By

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) dropped 3.8% on Friday after the company announced weaker than expected quarterly earnings. The company traded as low as $49.00 and last traded at $49.04. Approximately 2,777 shares changed hands during trading, a decline of 98% from the average daily volume of 142,041 shares. The stock had previously closed at $51.00.The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by ($0.15). The business had revenue of $20.10 million for the quarter, compared to analysts’ expectations of $25.05 million. Enanta Pharmaceuticals had a negative return on equity of 3.75% and a negative net margin of 29.53%. The company’s revenue for the quarter was down 27.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.30) earnings per share.

A number of brokerages have issued reports on ENTA. JPMorgan Chase & Co. upgraded shares of Enanta Pharmaceuticals from an “underweight” rating to a “neutral” rating and lifted their target price for the stock from $44.00 to $55.00 in a research report on Friday, January 29th. Zacks Investment Research lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 27th. Finally, Royal Bank of Canada boosted their price objective on shares of Enanta Pharmaceuticals from $47.00 to $53.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 9th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. Enanta Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $64.88.

(Ad)

Coinbase – the world’s largest digital currency exchange – just went public.

But this IPO is not the best way to make money in crypto in 2021.

Instead folks need to get in on a handful of valuable crypto plays…

3 of which I just named in a brand new free report, “3 Cryptos to Beat Bitcoin.”

Institutional investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund grew its holdings in Enanta Pharmaceuticals by 20.9% in the fourth quarter. New York State Common Retirement Fund now owns 37,898 shares of the biotechnology company’s stock valued at $1,596,000 after purchasing an additional 6,550 shares during the period. Tudor Investment Corp Et Al acquired a new stake in Enanta Pharmaceuticals in the fourth quarter valued at $1,856,000. Virtus ETF Advisers LLC raised its holdings in Enanta Pharmaceuticals by 18.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 14,321 shares of the biotechnology company’s stock valued at $603,000 after acquiring an additional 2,275 shares in the last quarter. Credit Suisse AG raised its holdings in shares of Enanta Pharmaceuticals by 8.3% during the fourth quarter. Credit Suisse AG now owns 37,837 shares of the biotechnology company’s stock worth $1,594,000 after purchasing an additional 2,892 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of Enanta Pharmaceuticals by 9.6% during the fourth quarter. Rhumbline Advisers now owns 65,257 shares of the biotechnology company’s stock worth $2,747,000 after purchasing an additional 5,698 shares during the period. Hedge funds and other institutional investors own 90.78% of the company’s stock.

The company has a market capitalization of $988.43 million, a price-to-earnings ratio of -28.02 and a beta of 0.54. The stock’s fifty day simple moving average is $50.52 and its two-hundred day simple moving average is $47.52.

About Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus.

Featured Story: What is a front-end load?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Why Invest in Dividend Kings

7 Hotel Stocks Just Waiting For the Vaccine

Like any group of stocks related to travel and tourism, hotel stocks saw a steep drop in share prices in 2020. The leisure and hospitality sector that once had 15 million employees has lost 4 million jobs since February.

Many major cities will be feeling the ripple effects of the Covid-19 pandemic for years. However, there is ample evidence that shows the pandemic may be coming to an end. The number of new cases is dropping. The number of those getting vaccinated is rising. And even in the cities with the most restrictive mitigation measures, the slow process of reopening is beginning.

All of this can’t come fast enough for individuals who rely on the travel and tourism industry for their livelihood. Hotel chains had at least some revenue coming in the door. And when earnings season concludes, the more budget-friendly hotel chains may realize revenue that is 75% of its 2019 numbers. But that is not enough to bring the hotels to anywhere near full employment. Particularly with hotels that have bars and restaurants that have remained closed or open at limited capacity.

Many economists are optimistic that travel may begin to look more normal by the summer of this year. And the global economy may deliver 6.4% GDP growth this year. With that in mind, the hotel chains with the best fundamentals and the broadest footprint will be in the best position as the economy reopens.

View the “7 Hotel Stocks Just Waiting For the Vaccine”.

Continue Reading

Pharmaceuticals

BioCryst Pharmaceuticals Stock – GuruFocus.com

Published

on

By

The stock of BioCryst Pharmaceuticals (NAS:BCRX, 30-year Financials) shows every sign of being significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus’ estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $13.12 per share and the market cap of $2.3 billion, BioCryst Pharmaceuticals stock is estimated to be significantly overvalued. GF Value for BioCryst Pharmaceuticals is shown in the chart below.

BioCryst Pharmaceuticals GF Value Chart

Because BioCryst Pharmaceuticals is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth.

Link: These companies may deliever higher future returns at reduced risk.

It is always important to check the financial strength of a company before buying its stock. Investing in companies with poor financial strength have a higher risk of permanent loss. Looking at the cash-to-debt ratio and interest coverage is a great way to understand the financial strength of a company. BioCryst Pharmaceuticals has a cash-to-debt ratio of 1.08, which is worse than 83% of the companies in Biotechnology industry. The overall financial strength of BioCryst Pharmaceuticals is 2 out of 10, which indicates that the financial strength of BioCryst Pharmaceuticals is poor. This is the debt and cash of BioCryst Pharmaceuticals over the past years:

debt and cash

Companies that have been consistently profitable over the long term offer less risk for investors who may want to purchase shares. Higher profit margins usually dictate a better investment compared to a company with lower profit margins. BioCryst Pharmaceuticals has been profitable 0 over the past 10 years. Over the past twelve months, the company had a revenue of $17.8 million and loss of $1.08 a share. Its operating margin is -981.12%, which ranks worse than 73% of the companies in Biotechnology industry. Overall, the profitability of BioCryst Pharmaceuticals is ranked 1 out of 10, which indicates poor profitability. This is the revenue and net income of BioCryst Pharmaceuticals over the past years:

Revnue and Net Income

Growth is probably one of the most important factors in the valuation of a company. GuruFocus’ research has found that growth is closely correlated with the long-term performance of a company’s stock. If a company’s business is growing, the company usually creates value for its shareholders, especially if the growth is profitable. Likewise, if a company’s revenue and earnings are declining, the value of the company will decrease. BioCryst Pharmaceuticals’s 3-year average revenue growth rate is worse than 73% of the companies in Biotechnology industry. BioCryst Pharmaceuticals’s 3-year average EBITDA growth rate is -14.4%, which ranks worse than 76% of the companies in Biotechnology industry.

Another way to look at the profitability of a company is to compare its return on invested capital and the weighted cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. We want to have the return on invested capital higher than the weighted cost of capital. For the past 12 months, BioCryst Pharmaceuticals’s return on invested capital is -295.87, and its cost of capital is 17.87. The historical ROIC vs WACC comparison of BioCryst Pharmaceuticals is shown below:

ROIC vs WACC

Overall, the stock of BioCryst Pharmaceuticals (NAS:BCRX, 30-year Financials) is believed to be significantly overvalued. The company’s financial condition is poor and its profitability is poor. Its growth ranks worse than 76% of the companies in Biotechnology industry. To learn more about BioCryst Pharmaceuticals stock, you can check out its 30-year Financials here.

To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.

Continue Reading

Pharmaceuticals

Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market

Published

on

By

Shares of Regeneron Pharmaceuticals Inc.
REGN,
-0.39%

shed 0.39% to $496.75 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index
SPX,
+0.74%

rising 0.74% to 4,232.60 and the Dow Jones Industrial Average
DJIA,
+0.66%

rising 0.66% to 34,777.76. Regeneron Pharmaceuticals Inc. closed $167.89 short of its 52-week high ($664.64), which the company reached on July 20th.

The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson
JNJ,
+0.45%

rose 0.45% to $168.50, Novartis AG ADR
NVS,
+0.70%

rose 0.70% to $87.96, and Amgen Inc.
AMGN,
+1.16%

rose 1.16% to $254.21. Trading volume (703,218) remained 165,258 below its 50-day average volume of 868,476.


Editor’s Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

Continue Reading

Trending